Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, Darrell White, MD, Martin Gyger, MD, Jonahtan Kaufmann, MD, Andrzej Jakubowiak, MD PhD, Engin Gul, BSc, Lisa W Le, MSc, Zhihua Li, Donna Reece, Vishal Kukreti, MD FRCPC, Richard LeBlanc

Blood (2015) 126 (23): 4234.

https://doi.org/10.1182/blood.V126.23.4234.4234

Published: 2015

Journal Articles

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Harminder Paul, Susi Snitzler, RN, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B. Gibson, PhD, Michelle L. Queau, B.Sc, Suzanne Trudel, MD

Blood (2015) 126 (23): 4163.

https://doi.org/10.1182/blood.V126.23.4163.4163

Published: 2015

Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith

Blood (2015) 126 (23): 1742.

https://doi.org/10.1182/blood.V126.23.1742.1742

Published: 2015

Journal Articles

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Christine I. Chen, MD, Susi Snitzler, RN, Trina Wang, RN, Harminder Paul, Lisa W Le, Ellen Nong Wei, MSc, Anthea Lau, Deborah A Smith, PharmD, Michelle Brown, James B Johnston, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4175.

https://doi.org/10.1182/blood.V122.21.4175.4175

Published: 2013

Journal Articles

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Christine Chen, MD, Harminder Paul, Luisa Del Rizzo, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B Gibson, PhD, Michelle Brown, Suzanne Trudel, MD

Blood (2012) 120 (21): 2895.

https://doi.org/10.1182/blood.V120.21.2895.2895

Published: 2012

Journal Articles

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD, Harminder Paul, Trina Wang, RN, Lisa W Le, MSc, Vishal Kukreti, MD, Ellen Nong Wei, Anthea Lau, P. Leif Bergsagel, MD, Nimisha Dave, Suzanne Trudel, MD

Blood (2012) 120 (21): 718.

https://doi.org/10.1182/blood.V120.21.718.718

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

NARROW

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Email alerts

ASH Publications

American Society of Hematology

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only